Dr. Armstrong on recent ARCHES data in metastatic hormone-sensitive prostate cancer
“We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,” says Andrew J. Armstrong, MD, MSc.
In this video, Andrew J. Armstrong, MD, MSc, discusses new data from the ARCHES trial, including “Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES,” which was presented at the 2022 American Society of Clinical Oncology Annual Meeting. Armstrong is a professor of medicine, professor in surgery, professor in pharmacology and cancer biology, and a member of the Duke Cancer Institute at Duke University in Durham, North Carolina.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
